REPH crashed 5/18 after an unexpected CRL for the IV version of its post operative pain drug. Here are REPH's other major assets and liabilities: Dexmedetomidine in Ph2 peri procedural pain Fadolamine in Ph2 for intrathecal injection EOQ-1/2018 Cash = ~$51mn Growing contract mnfring business that generated $19.5mn in Q1/18. Senior secured debt with interest expense running ~$2mn/Q